Author response: The clinical spectrum of Caspr2 antibody-associated disease

Neurology

Volumn 88, Issue 3, 2017, Pages 333-334

  Van Sonderen, Agnes ^a   Ariño, Helena ^a   Dalmau, Josep ^a   Titulaer, Maarten J ^a  

^a NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CONTACTIN ASSOCIATED PROTEIN LIKE 2 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; AUTOANTIBODY; NERVE PROTEIN;

ALLERGIC ENCEPHALITIS; ANTIBODY DETECTION; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; DISEASE ASSOCIATION; HUMAN; HYPONATREMIA; LETTER; MYOKYMIA; PARANEOPLASTIC NEUROPATHY; PRIORITY JOURNAL; SMALL CELL LUNG CANCER; THYMOMA;

ANTIBODIES; AUTOANTIBODIES; NERVE TISSUE PROTEINS;

EID: 85009893924     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003526     Document Type: Letter

References (5)

1. van Sonderen A, Ariño H, Petit-Pedrol M, et al. The clinical spectrum of Caspr2 antibody-Associated disease. Neurology 2016;87:521-528.
2. Joubert B, Saint-Martin M, Noraz N, et al. Characterization of a subtype of autoimmune encephalitis with anticontactin-Associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol 2016;73:1115-1124.
3. Hoftberger R, van Sonderen A, Leypoldt F, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology 2015;84:2403-2412.
4. Arino H, Armangue T, Petit-Pedrol M, et al. Anti-LGI1-Associated cognitive impairment: presentation and longterm outcome. Neurology 2016;87:759-765.
5. van Sonderen A, Thijs RD, Coenders EC, et al. Anti-LGI1 encephalitis: clinical syndrome and long-Term follow-up. Neurology 2016;87:1449-1456.